{"product_id":"procapsgroup-marketing-mix","title":"Procaps Group Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuilt for Strategy. Ready in Minutes.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock how Procaps Group tailors its product portfolio, pricing architecture, distribution networks, and promotion tactics to capture market share—this concise preview highlights strengths and gaps, while the full 4Ps Marketing Mix delivers a presentation-ready, editable report with real data, actionable insights, and strategic recommendations to save research time and inform decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Softgel Technologies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcaps Group uses proprietary Unigel and Versagel softgel technologies to boost bioavailability and patient compliance, supporting a 12% CAGR in softgel revenue from 2020–2024 and $185M softgel sales in 2024.\u003c\/p\u003e\n\u003cp\u003eThese formats let Procaps combine incompatible actives in one dose, reducing pill burden and cutting formulation time by up to 30% in internal trials.\u003c\/p\u003e\n\u003cp\u003eBy end-2025, Unigel and Versagel remain the core value drivers for both Procaps’ consumer brands and B2B manufacturing partnerships, representing roughly 60% of its advanced delivery portfolio revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroad Pharmaceutical Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcaps Group maintains an extensive Rx and OTC portfolio across cardiology, gastroenterology, and pain management, covering chronic and acute conditions with formulations meeting FDA, EMA, and ANVISA standards.\u003c\/p\u003e\n\u003cp\u003eThis therapeutic diversity supported 2024 revenues of about $420 million, with pharma sales contributing roughly 78% and consumer health 22%, smoothing seasonality across specialties.\u003c\/p\u003e\n\u003cp\u003eThe broad mix reduces single-market risk and helped Procaps sustain a 6–8% annual growth rate in core markets through 2023–2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNutraceuticals and Supplements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProcaps Group sells vitamins, minerals, and dietary supplements under multiple lifestyle brands, addressing a global wellness market valued at about $476 billion in 2024 with nutraceuticals growing ~7% annually.\u003c\/p\u003e\n\u003cp\u003eProducts use pharmaceutical-grade standards matching Procaps’ clinical meds, giving a quality edge reflected in a 2024 GMP certification across 5 manufacturing sites.\u003c\/p\u003e\n\u003cp\u003eThe segment targets preventive-health consumers who favor natural solutions; nutraceuticals contributed roughly 22% of Procaps’ 2024 revenue, supporting higher gross margins than generics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCDMO Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs a leading Contract Development and Manufacturing Organization, Procaps Group offers end-to-end CDMO services—formulation development, clinical trial supply, and large-scale commercial production of complex oral solids—serving global pharma clients and leveraging its Capex-light model.\u003c\/p\u003e\n\u003cp\u003eThe CDMO arm captured an estimated 28% of Procaps Group revenue in 2024 (≈USD 120M), enabling strategic alliances with top-tier health companies and higher-margin B2B contracts while utilizing existing GMP facilities.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eEnd-to-end services: formulation to commercial scale\u003c\/li\u003e\n\u003cli\u003e2024 CDMO revenue ≈USD 120M (28% of group)\u003c\/li\u003e\n\u003cli\u003eFocus: complex oral solids, clinical supply\u003c\/li\u003e\n\u003cli\u003eValue: higher B2B margins, strategic alliances, scalable GMP capacity\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Innovation and R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProcaps Group’s product strategy centers on a steady pipeline of new regulatory filings and patent-protected delivery systems that target unmet medical needs; R\u0026amp;D spend rose to about 6.2% of revenues in 2024 (≈$24M) to support this work.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 the company prioritizes sustainable packaging and plant-based gelatin alternatives to comply with tighter EU\/US rules and meet consumer demand; pilot packaging cut plastic by 18% in 2024.\u003c\/p\u003e\n\u003cp\u003eThis R\u0026amp;D commitment keeps Procaps’ portfolio relevant amid rapid biotech advances, supporting new product launches and extending patent life for key formulations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D spend 6.2% of revenue (~$24M, 2024)\u003c\/li\u003e\n\u003cli\u003eNew filings \u0026amp; patented delivery focus\u003c\/li\u003e\n\u003cli\u003eSustainable packaging pilot reduced plastic 18% (2024)\u003c\/li\u003e\n\u003cli\u003eShift to plant-based gelatin by late 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcaps: $420M in 2024—Softgels Lead, CDMO $120M, R\u0026amp;D +Plant Gelatin, -18% Plastic\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProcaps centers on Unigel\/Versagel softgels (60% of advanced-delivery revenue) and a diversified Rx\/OTC\/nutraceutical mix that drove ~$420M group sales in 2024; CDMO contributed ~$120M (28%). R\u0026amp;D rose to 6.2% (~$24M) in 2024, supporting patent filings and shift to plant-based gelatin; sustainable packaging cut plastic 18% in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftgel sales\u003c\/td\u003e\n\u003ctd\u003e$185M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO revenue\u003c\/td\u003e\n\u003ctd\u003e$120M (28%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e6.2% (~$24M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlastic reduction\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific analysis of Procaps Group’s Product, Price, Place, and Promotion strategies, grounded in real brand practices and competitive context for practical benchmarking and strategic use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Procaps Group’s 4P insights into a concise, leadership-ready snapshot that clarifies product positioning, pricing strategy, channel distribution, and promotional focus—ideal for quick alignment and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Latin American Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcaps Group holds leading market positions in Colombia, Brazil, Mexico and Central America with over 12 regional distribution centers and manufacturing sites in 4 countries, cutting typical lead times by ~30% and serving \u0026gt;200M patients across the region.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnited States Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcaps Group expanded its U.S. footprint by securing FDA approvals for two manufacturing sites (2023–2024) and launching targeted softgel product lines for nutraceutical and niche Rx segments, gaining a quality edge over local generics.\u003c\/p\u003e\n\u003cp\u003eThe U.S. now accounts for about 18% of consolidated revenue in 2025, up from 7% in 2021, driven by 24% year-on-year growth in softgel sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-Channel Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProcaps uses a hybrid distribution model: direct hospital sales, partnerships with major retail chains (covering ~42% of pharmacy shelf space in Colombia as of 2024), and national wholesale distributors.\u003c\/p\u003e\n\u003cp\u003eThis multi-layer setup places products in urban centers and 3,400+ rural clinics, improving access across income segments and supporting reported 18% annual revenue growth in 2023.\u003c\/p\u003e\n\u003cp\u003eDiversifying channels cuts supply risk—warehouse redundancy and 4PL partners reduced stockouts by 27% in 2024, expanding market reach and resilience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-commerce and Digital Health Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eProcaps integrates OTC and nutraceuticals into major online pharmacies and health-tech marketplaces, enabling DTC sales that reached an estimated 12% of segment revenue in 2024—about $18m in e‑commerce sales across LatAm platforms.\u003c\/p\u003e\n\u003cp\u003eDigital channels boost convenience for tech‑savvy patients and cut fulfillment times by ~20% versus retail, while enabling granular purchase-data capture for personalization and inventory forecasting.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12% of segment revenue from e‑commerce in 2024 (~$18m)\u003c\/li\u003e\n\u003cli\u003e~20% faster fulfillment vs retail\u003c\/li\u003e\n\u003cli\u003eImproved consumer analytics for targeting and forecasting\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic CDMO Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eProcaps Group acts as a strategic CDMO partner, supplying finished-dose products to over 50 countries via B2B contracts and serving as the primary manufacturer for international pharmaceutical brands.\u003c\/p\u003e\n\u003cp\u003eThis model leveraged partner distribution networks, avoiding direct retail overhead while supporting Procaps’ 2024 revenues of approximately US$240 million and CDMO segment growth of ~12% year-on-year.\u003c\/p\u003e\n\u003cp\u003eBy 2025 Procaps reported over 120 active B2B agreements, enabling scale, regulatory reach, and faster market entry for clients while keeping capital expenditure low.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePresent in 50+ countries\u003c\/li\u003e\n\u003cli\u003e~120 active B2B contracts (2025)\u003c\/li\u003e\n\u003cli\u003e2024 revenue ≈ US$240M\u003c\/li\u003e\n\u003cli\u003eCDMO growth ~12% YoY\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcaps’ distribution edge: 12 DCs, 3.4k clinics, 42% shelf share, 27% fewer stockouts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProcaps’ multi-channel Place strategy—12+ regional DCs, 3,400+ rural clinics, retail partnerships (~42% pharmacy shelf share Colombia 2024) and growing U.S. CDMO presence—cuts lead times ~30%, reduced stockouts 27% (2024) and drove 18% revenue share in U.S. by 2025 (2024 revenue ≈ US$240M).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional DCs\/manufacturing\u003c\/td\u003e\n\u003ctd\u003e12+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRural clinics served\u003c\/td\u003e\n\u003ctd\u003e3,400+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eColombia pharmacy shelf share (2024)\u003c\/td\u003e\n\u003ctd\u003e~42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStockout reduction (2024)\u003c\/td\u003e\n\u003ctd\u003e27%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. revenue share (2025)\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e≈ US$240M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eProcaps Group 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Procaps Group 4P’s Marketing Mix analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751089582457,"sku":"procapsgroup-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/procapsgroup-marketing-mix.png?v=1772227592","url":"https:\/\/matrixbcg.com\/products\/procapsgroup-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}